Status: Recruiting
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Participants needed: 204
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Telix Pharmaceuticals (Innovations) Pty LimitedUpdated: Sep 10, 2025Locations: 1
Eligibility criteria
Male, at least 18 years old. [+7]
Has had prior treatment for PCa or prior diagnosis of csPCa. [+11]